Clinical Laserthermia Systems: Exciting Year Ahead

Research Update

2020-02-14

07:30

Redeye resumes coverage of CLS after the successful SEK 62 million capital raising (where we acted as financial advisor) and produce a base case of SEK 10 per share. Strong investor interest in the rights issue combined with several potential catalysts in the year ahead, in our view, provide an attractive backdrop to the current investment case.

EN

LS

Erik Nordström

Ludvig Svensson

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.